Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-targeted therapy for Richter transformation to diffuse large B-cell lymphoma
ChiCTR2500109894Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zanubrutinib, tislelizumab, glofitamab, obinutuzumab and lenalidomide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective response rate at end of 6 treatment courses. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
zanubrutinibtislelizumabglofitamabobinutuzumablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2500109894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109894.